| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Xylans | 19 | 2025 | 26 | 8.620 |
Why?
|
| Apoptosis | 25 | 2025 | 1541 | 4.730 |
Why?
|
| Carcinoma, Ehrlich Tumor | 7 | 2020 | 18 | 3.230 |
Why?
|
| Saccharomyces cerevisiae | 9 | 2019 | 199 | 2.430 |
Why?
|
| Dendritic Cells | 6 | 2019 | 130 | 2.220 |
Why?
|
| Antioxidants | 8 | 2024 | 439 | 2.170 |
Why?
|
| Oxidative Stress | 11 | 2025 | 990 | 2.020 |
Why?
|
| Probiotics | 4 | 2020 | 37 | 1.920 |
Why?
|
| Breast Neoplasms | 13 | 2022 | 1679 | 1.850 |
Why?
|
| Radiation Injuries | 3 | 2024 | 23 | 1.650 |
Why?
|
| Lactobacillus | 3 | 2020 | 22 | 1.580 |
Why?
|
| Paclitaxel | 4 | 2019 | 64 | 1.570 |
Why?
|
| Animals | 35 | 2025 | 16695 | 1.370 |
Why?
|
| Liver | 4 | 2022 | 503 | 1.310 |
Why?
|
| Mice | 22 | 2025 | 6490 | 1.280 |
Why?
|
| Streptozocin | 4 | 2022 | 26 | 1.240 |
Why?
|
| CD4-Positive T-Lymphocytes | 6 | 2019 | 276 | 1.230 |
Why?
|
| Iron | 4 | 2024 | 247 | 1.210 |
Why?
|
| Alzheimer Disease | 3 | 2021 | 972 | 1.200 |
Why?
|
| Stomach Neoplasms | 3 | 2016 | 228 | 1.200 |
Why?
|
| Antineoplastic Agents | 6 | 2020 | 979 | 1.160 |
Why?
|
| Anti-Inflammatory Agents | 2 | 2021 | 184 | 1.130 |
Why?
|
| Cell Line, Tumor | 21 | 2022 | 2598 | 1.110 |
Why?
|
| CD8-Positive T-Lymphocytes | 4 | 2018 | 181 | 1.090 |
Why?
|
| Cytokines | 10 | 2024 | 661 | 1.090 |
Why?
|
| Flow Cytometry | 14 | 2021 | 411 | 1.080 |
Why?
|
| Rats, Wistar | 8 | 2025 | 282 | 1.070 |
Why?
|
| Radiation-Protective Agents | 3 | 2024 | 14 | 1.060 |
Why?
|
| Diabetes Mellitus, Experimental | 3 | 2024 | 126 | 1.050 |
Why?
|
| Aging | 4 | 2020 | 764 | 1.030 |
Why?
|
| Cell Proliferation | 9 | 2022 | 1420 | 1.000 |
Why?
|
| bcl-2-Associated X Protein | 7 | 2021 | 76 | 0.990 |
Why?
|
| Trifolium | 2 | 2024 | 2 | 0.980 |
Why?
|
| Polyethylene | 1 | 2025 | 4 | 0.940 |
Why?
|
| Platinum | 3 | 2017 | 23 | 0.930 |
Why?
|
| Plasmalogens | 1 | 2025 | 3 | 0.930 |
Why?
|
| Sodium Glutamate | 1 | 2025 | 5 | 0.930 |
Why?
|
| Thymus Extracts | 3 | 2009 | 5 | 0.930 |
Why?
|
| Iron Compounds | 2 | 2019 | 4 | 0.910 |
Why?
|
| Cultured Milk Products | 2 | 2015 | 2 | 0.910 |
Why?
|
| Hepatocytes | 1 | 2025 | 79 | 0.900 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 1 | 2025 | 105 | 0.890 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 8 | 2016 | 152 | 0.860 |
Why?
|
| Minerals | 2 | 2018 | 52 | 0.850 |
Why?
|
| MAP Kinase Signaling System | 1 | 2025 | 189 | 0.810 |
Why?
|
| Killer Cells, Natural | 6 | 2021 | 99 | 0.800 |
Why?
|
| Adenocarcinoma | 3 | 2019 | 287 | 0.800 |
Why?
|
| Lymphocyte Activation | 5 | 2018 | 244 | 0.800 |
Why?
|
| Hematologic Diseases | 2 | 2013 | 13 | 0.800 |
Why?
|
| Spleen | 4 | 2019 | 199 | 0.800 |
Why?
|
| Nanoparticles | 2 | 2025 | 449 | 0.770 |
Why?
|
| Dietary Supplements | 2 | 2021 | 208 | 0.750 |
Why?
|
| Phagocytosis | 8 | 2008 | 83 | 0.750 |
Why?
|
| NF-kappa B | 1 | 2025 | 355 | 0.750 |
Why?
|
| Immunoglobulin A, Secretory | 1 | 2021 | 16 | 0.730 |
Why?
|
| Placental Extracts | 1 | 2021 | 2 | 0.730 |
Why?
|
| Methotrexate | 1 | 2021 | 22 | 0.720 |
Why?
|
| Respiratory Tract Infections | 1 | 2021 | 36 | 0.720 |
Why?
|
| Immunity, Mucosal | 1 | 2021 | 52 | 0.710 |
Why?
|
| Fermentation | 1 | 2021 | 38 | 0.710 |
Why?
|
| DNA Damage | 6 | 2020 | 358 | 0.710 |
Why?
|
| Immunosuppressive Agents | 1 | 2021 | 94 | 0.690 |
Why?
|
| Anti-Infective Agents | 1 | 2021 | 74 | 0.690 |
Why?
|
| Intestinal Mucosa | 1 | 2021 | 131 | 0.670 |
Why?
|
| Immunity, Innate | 1 | 2021 | 168 | 0.670 |
Why?
|
| Placenta | 1 | 2021 | 113 | 0.670 |
Why?
|
| Cognition | 2 | 2021 | 458 | 0.670 |
Why?
|
| Coated Materials, Biocompatible | 2 | 2010 | 22 | 0.660 |
Why?
|
| Immunomodulation | 1 | 2020 | 13 | 0.660 |
Why?
|
| Liver Neoplasms, Experimental | 1 | 2020 | 21 | 0.650 |
Why?
|
| Female | 23 | 2022 | 24018 | 0.620 |
Why?
|
| Seawater | 2 | 2018 | 53 | 0.620 |
Why?
|
| Antiviral Agents | 2 | 2023 | 189 | 0.620 |
Why?
|
| Whole-Body Irradiation | 2 | 2024 | 9 | 0.620 |
Why?
|
| Mammary Neoplasms, Animal | 1 | 2019 | 29 | 0.610 |
Why?
|
| Biological Products | 1 | 2020 | 91 | 0.580 |
Why?
|
| Leukocytes, Mononuclear | 3 | 2024 | 246 | 0.580 |
Why?
|
| Humans | 31 | 2024 | 42163 | 0.580 |
Why?
|
| Paracrine Communication | 1 | 2018 | 18 | 0.560 |
Why?
|
| Rats | 8 | 2025 | 3701 | 0.560 |
Why?
|
| Neuroprotective Agents | 1 | 2021 | 267 | 0.560 |
Why?
|
| Membrane Potential, Mitochondrial | 5 | 2022 | 89 | 0.550 |
Why?
|
| Male | 16 | 2025 | 22779 | 0.530 |
Why?
|
| Antineoplastic Agents, Phytogenic | 2 | 2016 | 134 | 0.530 |
Why?
|
| Cells, Cultured | 7 | 2019 | 1617 | 0.530 |
Why?
|
| Adjuvants, Immunologic | 1 | 2018 | 117 | 0.530 |
Why?
|
| Glutathione | 5 | 2024 | 170 | 0.520 |
Why?
|
| Bacterial Proteins | 1 | 2021 | 580 | 0.520 |
Why?
|
| Viremia | 1 | 2016 | 44 | 0.510 |
Why?
|
| Radiation Tolerance | 2 | 2013 | 12 | 0.510 |
Why?
|
| Keratinocytes | 1 | 2017 | 67 | 0.510 |
Why?
|
| Hepatitis C, Chronic | 1 | 2016 | 44 | 0.500 |
Why?
|
| Stomach | 1 | 2016 | 50 | 0.490 |
Why?
|
| Lipid Peroxidation | 4 | 2021 | 141 | 0.470 |
Why?
|
| Brain | 2 | 2021 | 1452 | 0.460 |
Why?
|
| Protective Agents | 1 | 2015 | 26 | 0.450 |
Why?
|
| Disease Models, Animal | 4 | 2021 | 1554 | 0.450 |
Why?
|
| Drug Resistance, Neoplasm | 2 | 2014 | 290 | 0.440 |
Why?
|
| Leukemia, Myeloid | 1 | 2014 | 9 | 0.430 |
Why?
|
| Cell Cycle | 3 | 2020 | 348 | 0.430 |
Why?
|
| Tumor Burden | 3 | 2019 | 84 | 0.430 |
Why?
|
| Malondialdehyde | 3 | 2021 | 42 | 0.430 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2022 | 744 | 0.420 |
Why?
|
| Gamma Rays | 3 | 2024 | 27 | 0.420 |
Why?
|
| Esophageal Neoplasms | 1 | 2015 | 137 | 0.400 |
Why?
|
| Hematopoietic System | 1 | 2013 | 2 | 0.400 |
Why?
|
| Quercetin | 2 | 2024 | 46 | 0.390 |
Why?
|
| Mitochondria | 4 | 2015 | 516 | 0.380 |
Why?
|
| Caspase 3 | 3 | 2021 | 226 | 0.380 |
Why?
|
| Signal Transduction | 5 | 2025 | 2111 | 0.370 |
Why?
|
| Candida albicans | 2 | 2004 | 173 | 0.360 |
Why?
|
| Cell Line | 3 | 2025 | 1416 | 0.350 |
Why?
|
| Antigens, CD | 4 | 2015 | 122 | 0.350 |
Why?
|
| Cell Survival | 3 | 2025 | 934 | 0.350 |
Why?
|
| Lymphocytes | 2 | 2009 | 124 | 0.340 |
Why?
|
| Dose-Response Relationship, Drug | 6 | 2013 | 1112 | 0.340 |
Why?
|
| T-Lymphocytes | 2 | 2010 | 378 | 0.330 |
Why?
|
| Immune System Diseases | 1 | 2010 | 21 | 0.320 |
Why?
|
| Nanofibers | 1 | 2010 | 14 | 0.320 |
Why?
|
| Hippocampus | 2 | 2025 | 591 | 0.310 |
Why?
|
| Calcium | 2 | 2009 | 487 | 0.300 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2010 | 158 | 0.290 |
Why?
|
| Daunorubicin | 1 | 2008 | 3 | 0.290 |
Why?
|
| Liver Neoplasms | 1 | 2010 | 211 | 0.280 |
Why?
|
| Aged | 4 | 2024 | 7982 | 0.280 |
Why?
|
| Combined Modality Therapy | 2 | 2019 | 174 | 0.280 |
Why?
|
| Body Weight | 3 | 2019 | 428 | 0.270 |
Why?
|
| Yeast, Dried | 1 | 2007 | 1 | 0.270 |
Why?
|
| Inflammation | 3 | 2024 | 729 | 0.270 |
Why?
|
| Organ Size | 2 | 2019 | 167 | 0.270 |
Why?
|
| Metal Nanoparticles | 1 | 2010 | 227 | 0.260 |
Why?
|
| Lysosomal-Associated Membrane Protein 1 | 2 | 2018 | 3 | 0.260 |
Why?
|
| Double-Blind Method | 2 | 2021 | 305 | 0.250 |
Why?
|
| Interferon-gamma | 3 | 2016 | 268 | 0.250 |
Why?
|
| Coculture Techniques | 3 | 2018 | 105 | 0.240 |
Why?
|
| Methylnitronitrosoguanidine | 2 | 2016 | 7 | 0.240 |
Why?
|
| Plant Extracts | 3 | 2024 | 303 | 0.230 |
Why?
|
| Tongue Neoplasms | 1 | 2005 | 9 | 0.230 |
Why?
|
| Fungi | 1 | 2006 | 103 | 0.230 |
Why?
|
| Immunologic Factors | 1 | 2004 | 50 | 0.220 |
Why?
|
| Testicular Diseases | 1 | 2024 | 1 | 0.220 |
Why?
|
| Portulaca | 1 | 2024 | 3 | 0.220 |
Why?
|
| Enzyme Activation | 4 | 2008 | 462 | 0.220 |
Why?
|
| Caspases | 4 | 2005 | 148 | 0.210 |
Why?
|
| Leukemia, T-Cell | 1 | 2003 | 6 | 0.210 |
Why?
|
| Middle Aged | 4 | 2024 | 11819 | 0.210 |
Why?
|
| Chemotherapy, Adjuvant | 2 | 2017 | 53 | 0.210 |
Why?
|
| Hypoglycemic Agents | 2 | 2024 | 181 | 0.210 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2005 | 187 | 0.200 |
Why?
|
| Mice, Inbred C57BL | 4 | 2010 | 1804 | 0.200 |
Why?
|
| Papain | 1 | 2023 | 5 | 0.200 |
Why?
|
| Peptide Hydrolases | 1 | 2023 | 44 | 0.200 |
Why?
|
| Computer Simulation | 1 | 2025 | 404 | 0.200 |
Why?
|
| Vero Cells | 1 | 2023 | 109 | 0.190 |
Why?
|
| Neoplasm Invasiveness | 1 | 2004 | 284 | 0.190 |
Why?
|
| Colonic Neoplasms | 1 | 2005 | 223 | 0.190 |
Why?
|
| Blotting, Western | 3 | 2009 | 884 | 0.190 |
Why?
|
| Glucose Transport Proteins, Facilitative | 1 | 2022 | 13 | 0.190 |
Why?
|
| Hesperidin | 1 | 2022 | 6 | 0.190 |
Why?
|
| Carbohydrate Metabolism | 1 | 2022 | 26 | 0.190 |
Why?
|
| Receptor, Insulin | 1 | 2022 | 26 | 0.190 |
Why?
|
| Cerebral Cortex | 1 | 2024 | 303 | 0.190 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2024 | 297 | 0.180 |
Why?
|
| Insulin Resistance | 1 | 2024 | 199 | 0.180 |
Why?
|
| Receptors, Retinoic Acid | 1 | 2021 | 27 | 0.180 |
Why?
|
| Intestine, Small | 1 | 2021 | 25 | 0.180 |
Why?
|
| Ovalbumin | 1 | 2021 | 47 | 0.180 |
Why?
|
| Egypt | 1 | 2021 | 53 | 0.180 |
Why?
|
| Liver Function Tests | 1 | 2021 | 19 | 0.180 |
Why?
|
| Aspartate Aminotransferases | 1 | 2021 | 15 | 0.180 |
Why?
|
| Ubiquitins | 1 | 2021 | 47 | 0.180 |
Why?
|
| Cholera Toxin | 1 | 2021 | 41 | 0.180 |
Why?
|
| AMP-Activated Protein Kinases | 1 | 2022 | 64 | 0.180 |
Why?
|
| Alanine Transaminase | 1 | 2021 | 26 | 0.180 |
Why?
|
| Seasons | 1 | 2021 | 133 | 0.180 |
Why?
|
| Oxidation-Reduction | 2 | 2015 | 448 | 0.170 |
Why?
|
| Interleukin-2 Receptor alpha Subunit | 2 | 2010 | 17 | 0.170 |
Why?
|
| Diethylnitrosamine | 1 | 2020 | 1 | 0.170 |
Why?
|
| Janus Kinase 2 | 1 | 2020 | 33 | 0.170 |
Why?
|
| Chemoprevention | 1 | 2020 | 41 | 0.160 |
Why?
|
| Insulin | 1 | 2022 | 255 | 0.160 |
Why?
|
| tau Proteins | 1 | 2021 | 182 | 0.160 |
Why?
|
| Maze Learning | 1 | 2020 | 112 | 0.160 |
Why?
|
| X-Rays | 1 | 2019 | 19 | 0.160 |
Why?
|
| Mice, Inbred BALB C | 1 | 2021 | 686 | 0.160 |
Why?
|
| Seeds | 1 | 2020 | 46 | 0.160 |
Why?
|
| Prostatic Neoplasms | 1 | 2009 | 1068 | 0.160 |
Why?
|
| NF-E2-Related Factor 2 | 1 | 2021 | 89 | 0.160 |
Why?
|
| DNA Fragmentation | 1 | 2019 | 95 | 0.160 |
Why?
|
| STAT3 Transcription Factor | 1 | 2020 | 97 | 0.160 |
Why?
|
| Down-Regulation | 2 | 2016 | 452 | 0.150 |
Why?
|
| Autophagy | 1 | 2020 | 136 | 0.150 |
Why?
|
| Up-Regulation | 1 | 2021 | 534 | 0.150 |
Why?
|
| Pilot Projects | 1 | 2021 | 733 | 0.150 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2020 | 160 | 0.150 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2015 | 933 | 0.150 |
Why?
|
| Lung | 1 | 2021 | 484 | 0.150 |
Why?
|
| Incidence | 1 | 2021 | 1054 | 0.150 |
Why?
|
| Treatment Outcome | 2 | 2013 | 1586 | 0.140 |
Why?
|
| Epithelial Cells | 1 | 2021 | 426 | 0.140 |
Why?
|
| Behavior, Animal | 1 | 2021 | 369 | 0.140 |
Why?
|
| HLA-DR Antigens | 1 | 2018 | 23 | 0.140 |
Why?
|
| Crystallization | 1 | 2018 | 88 | 0.140 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2019 | 233 | 0.130 |
Why?
|
| Amino Acid Chloromethyl Ketones | 2 | 2008 | 8 | 0.130 |
Why?
|
| Nerve Growth Factor | 1 | 2017 | 28 | 0.130 |
Why?
|
| TRPV Cation Channels | 1 | 2017 | 24 | 0.130 |
Why?
|
| Ribavirin | 1 | 2016 | 20 | 0.130 |
Why?
|
| Drug Agonism | 1 | 2016 | 1 | 0.130 |
Why?
|
| Age Factors | 1 | 2020 | 1139 | 0.130 |
Why?
|
| Reactive Oxygen Species | 2 | 2010 | 518 | 0.120 |
Why?
|
| Drug Synergism | 2 | 2008 | 189 | 0.120 |
Why?
|
| Gastric Mucosa | 1 | 2016 | 64 | 0.120 |
Why?
|
| Drug Therapy, Combination | 1 | 2016 | 233 | 0.120 |
Why?
|
| Microscopy, Electron, Transmission | 1 | 2016 | 160 | 0.120 |
Why?
|
| Integrin alpha Chains | 1 | 2015 | 3 | 0.120 |
Why?
|
| Pregnancy | 1 | 2021 | 1737 | 0.120 |
Why?
|
| Cost-Benefit Analysis | 1 | 2016 | 176 | 0.120 |
Why?
|
| Viral Load | 1 | 2016 | 344 | 0.110 |
Why?
|
| Free Radicals | 1 | 2015 | 72 | 0.110 |
Why?
|
| Gene Expression Regulation | 1 | 2019 | 1066 | 0.110 |
Why?
|
| HL-60 Cells | 1 | 2014 | 33 | 0.110 |
Why?
|
| Drug Resistance, Multiple | 1 | 2014 | 28 | 0.110 |
Why?
|
| Cichlids | 1 | 2013 | 5 | 0.100 |
Why?
|
| Membrane Potentials | 2 | 2004 | 221 | 0.100 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 2013 | 39 | 0.100 |
Why?
|
| Diet | 1 | 2019 | 810 | 0.100 |
Why?
|
| Radiation Dosage | 1 | 2013 | 37 | 0.100 |
Why?
|
| Tumor Cells, Cultured | 1 | 2014 | 506 | 0.100 |
Why?
|
| Survival Rate | 1 | 2013 | 353 | 0.090 |
Why?
|
| California | 1 | 2013 | 531 | 0.090 |
Why?
|
| Ethiodized Oil | 1 | 2010 | 3 | 0.090 |
Why?
|
| Chemoembolization, Therapeutic | 1 | 2010 | 6 | 0.090 |
Why?
|
| alpha-Fetoproteins | 1 | 2010 | 31 | 0.090 |
Why?
|
| Administration, Cutaneous | 1 | 2010 | 48 | 0.080 |
Why?
|
| Catheter Ablation | 1 | 2010 | 34 | 0.080 |
Why?
|
| Thyrotropin | 1 | 2010 | 23 | 0.080 |
Why?
|
| Antigens, Differentiation, T-Lymphocyte | 1 | 2010 | 9 | 0.080 |
Why?
|
| Diamond | 1 | 2010 | 9 | 0.080 |
Why?
|
| Housing, Animal | 1 | 2010 | 12 | 0.080 |
Why?
|
| Doxorubicin | 1 | 2010 | 95 | 0.080 |
Why?
|
| Lectins, C-Type | 1 | 2010 | 37 | 0.080 |
Why?
|
| Dose-Response Relationship, Immunologic | 1 | 2009 | 25 | 0.080 |
Why?
|
| Neoplasm Staging | 1 | 2010 | 366 | 0.080 |
Why?
|
| Drinking | 1 | 2009 | 35 | 0.080 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2010 | 150 | 0.080 |
Why?
|
| Administration, Oral | 1 | 2010 | 256 | 0.080 |
Why?
|
| Trypan Blue | 1 | 2009 | 2 | 0.080 |
Why?
|
| Cell Count | 1 | 2009 | 140 | 0.080 |
Why?
|
| Cell Shape | 1 | 2009 | 42 | 0.080 |
Why?
|
| Weight Gain | 1 | 2010 | 138 | 0.080 |
Why?
|
| Beverages | 1 | 2009 | 65 | 0.070 |
Why?
|
| B-Lymphocytes | 1 | 2009 | 183 | 0.070 |
Why?
|
| Caspase 9 | 1 | 2008 | 30 | 0.070 |
Why?
|
| Ethanol | 1 | 2010 | 221 | 0.070 |
Why?
|
| Caspase 8 | 1 | 2008 | 32 | 0.070 |
Why?
|
| Prevalence | 1 | 2013 | 1597 | 0.070 |
Why?
|
| Monocytes | 1 | 2010 | 275 | 0.070 |
Why?
|
| Hydrogen Peroxide | 1 | 2009 | 193 | 0.070 |
Why?
|
| Lipopolysaccharides | 1 | 2009 | 235 | 0.070 |
Why?
|
| Cytoplasm | 1 | 2008 | 154 | 0.070 |
Why?
|
| Injections, Intraperitoneal | 1 | 2008 | 58 | 0.070 |
Why?
|
| Adult | 2 | 2016 | 13458 | 0.070 |
Why?
|
| Random Allocation | 1 | 2008 | 145 | 0.070 |
Why?
|
| Transplantation, Heterologous | 1 | 2007 | 98 | 0.070 |
Why?
|
| Phenotype | 1 | 2009 | 774 | 0.060 |
Why?
|
| Mycelium | 1 | 2006 | 5 | 0.060 |
Why?
|
| Nitric Oxide | 1 | 2009 | 381 | 0.060 |
Why?
|
| Mice, Nude | 1 | 2007 | 403 | 0.060 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2008 | 379 | 0.060 |
Why?
|
| U937 Cells | 1 | 2005 | 30 | 0.060 |
Why?
|
| Caco-2 Cells | 1 | 2005 | 59 | 0.060 |
Why?
|
| Mice, Inbred C3H | 1 | 2004 | 80 | 0.060 |
Why?
|
| Risk Factors | 1 | 2013 | 3942 | 0.060 |
Why?
|
| Isoenzymes | 1 | 2005 | 169 | 0.050 |
Why?
|
| Plants, Edible | 1 | 2024 | 4 | 0.050 |
Why?
|
| Intracellular Membranes | 1 | 2004 | 37 | 0.050 |
Why?
|
| Respiratory Burst | 1 | 2004 | 5 | 0.050 |
Why?
|
| Aged, 80 and over | 1 | 2010 | 2803 | 0.050 |
Why?
|
| K562 Cells | 1 | 2003 | 32 | 0.050 |
Why?
|
| Acid Phosphatase | 1 | 2003 | 23 | 0.050 |
Why?
|
| Neoplasm Metastasis | 1 | 2004 | 233 | 0.050 |
Why?
|
| Cholesterol | 1 | 2024 | 230 | 0.050 |
Why?
|
| Sensitivity and Specificity | 1 | 2004 | 602 | 0.050 |
Why?
|
| Blood Glucose | 1 | 2024 | 386 | 0.050 |
Why?
|
| Macrophages | 1 | 2005 | 515 | 0.040 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2004 | 1737 | 0.040 |
Why?
|
| Time Factors | 1 | 2003 | 1848 | 0.040 |
Why?
|